



Patent Application
Attorney Docket No.9517H

By Tracy Mycroft
(Signature of person mailing)
Tracy Mycroft
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David B. MacLean et al. :

APPLICATION NO.: 10/615,282 : Examiner: To be Assigned

FILING DATE: 7/7/2003 : Group Art Unit: 1614

TITLE: Use of Estrogen Antagonists and Estrogen :
Agonists in Inhibiting Pathological Conditions

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date: 10/28/2003

Respectfully submitted,

Todd M. Crissey

Todd M. Crissey
Attorney for Applicant(s)
Reg. No. 37,807

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC9517H	SERIAL NO. 10/615,282
	APPLICANT David B. MacLean, et al.	
	FILING DATE 7/7/2003	GROUP 1614

U.S. PATENT DOCUMENTS													
	US	3	2	3	4	0	9	0	2/8/66	Charles F. Huebner	167	58	
	US	3	2	7	4	2	1	3	9/20/66	Daniel Lednicer	260	326.5	
	US	3	2	7	7	1	0	6	10/4/66	William L. Bencze	260	295	
	US	3	2	9	3	2	6	3	12/20/66	Daniel Lednicer	260	326.5	
	US	3	3	2	0	2	7	1	5/16/67	Daniel Lednicer	260	307	
	US	3	3	9	6	1	6	9	8/6/68	Daniel Lednicer	260	294.7	
	US	3	4	8	3	2	9	3	12/9/69	Gordon W. Duncan	424	274	
	US	3	5	6	7	7	3	7	3/2/71	Daniel Lednicer	37	00	
	US	3	8	6	2	2	3	2	1/21/75	Daniel Lednicer	260	570.7	
	US	4	1	3	3	8	1	4	1/9/79	C. David Jones	260	326.55	
	US	4	3	5	8	5	9	3	11/9/82	Jones, et al.	546	202	
	US	4	3	8	0	6	3	5	4/19/83	Mary K. Peters	546	202	
	US	4	4	1	8	0	6	8	11/29/83	Charles D. Jones	424	267	
	US	4	8	5	9	5	8	5	8/22/89	Sonnenschein et al.	435	29	
	US	5	0	4	7	4	3	1	9/10/91	Schickaneder et al.	514	648	
	US	5	2	5	4	5	9	4	10/19/93	Niikura et al.	514	648	
	US	5	3	6	4	7	9	1	11/15/94	Vegeto et al.	435	320.1	
	US	5	3	8	4	3	3	2	1/24/95	Steven A. Fontana	514	648	
	US	5	3	8	9	6	7	0	2/14/95	Steven A. Fontana	514	443	
	US	5	3	9	1	5	5	7	2/21/95	Cullinan et al.	514	324	
	US	5	3	9	3	7	6	3	2/28/95	Black et al.	514	333	
	US	5	4	1	8	2	5	2	5/23/95	Daniel C. Williams	514	443	
	US	5	4	3	4	1	6	6	7/18/95	A.L. Glasebrook	514	317	
	US	5	4	3	9	9	2	3	8/8/95	George J. Cullinan	514	324	
	US	5	4	3	9	9	3	1	8/8/95	James J. Sales	514	443	
	US	5	4	4	1	9	6	6	8/15/95	Jeffrey A. Dodge	514	324	
	US	5	4	4	1	9	8	6	8/15/95	David D. Thompson	514	648	
	US	5	4	4	6	0	5	3	8/29/95	Patrick Keohane	514	324	



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC9517H	SERIAL NO.10/615,282
APPLICANT David B. MacLean, et al.		
FILING DATE 7/7/2003		GROUP 1614

	US	6	4	0	3	6	1	1	6/11/02	MacLean et al.	514	315	
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	3	0	9	4	7	3	4/5/89	European	A61L	33/00		
	EP	0	6	0	5	1	9	3	7/6/94	European	A61K	31/40		
	EP	0	6	1	7	0	3	0	9/28/94	European	Co7D	333/56		
	EP	0	6	3	5	2	6	4	1/25/95	European	A61K	31/38		
	EP	0	6	5	2	0	0	4	5/10/95	European	A61K	31/4465		
	EP	0	6	5	9	4	1	1	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	3	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	4	6/28/95	European	A61K	34/445		
	EP	0	6	5	9	4	1	5	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	8	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	9	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	5	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	7	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	8	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	9	6/28/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	1	7/26/95	European	A61K	31/4535		
	EP	0	6	6	4	1	2	3	7/26/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	5	7/26/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	6	7/26/95	European	A61K	31/445		
	EP	0	7	9	2	6	4	0	09/03/97	European	A61K	31/135		
/	EP	0	7	9	2	6	4	1	9/3/97	European	A61K	31/40		
	WO	9	3	0	7	1	4	9	4/15/93	International	C07D	487/04		
	WO	9	5	1	0	5	1	3	4/20/95	International	C07D	333/56		



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC9517H	SERIAL NO.10/615,282
			APPLICANT David B. MacLean, et al.	
			FILING DATE 7/7/2003	GROUP 1614
			Endometriosis in the Rat", Volume 114 pages 379-382 (1987)	
			Osteoporosis Conference, SCRIP No. 1812/13, April 16 th /20 th pages 29-30 (1993)	
			Roland Loser et al., <u>Eur. J. Cancer Clin. Oncol.</u> , "In Vivo and In Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Volume 21, No. 8, pages 985-990 (1985)	
			Urs Eppenberger et al., <u>Am. J. Clin. Oncol.</u> , "Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen", Volume 14, Suppl. 2, S5-S14 (1991)	
EXAMINER				
DATE CONSIDERED				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE